

**Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF**

**Boulogne-Billancourt (France), January 8<sup>th</sup>, 2024** – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2023, the following resources were included to the dedicated liquidity account:

- 22,044 shares
- €2,808,813.12

It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:

- 12,751 shares
- €3,137,934.80

Between July 1<sup>st</sup>, 2023 and December 31<sup>st</sup>, 2023 have been executed:

- 2,722 purchase transactions
- 2,325 sell transactions

Under the same period, the volumes traded represented:

- 333,410 shares and €37,801,851.90 to the purchase
- 328,714 shares and €37,259,819.00 to the sell

---

**About Ipsen**

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit [ipсен.com](https://www.ipсен.com).

**Ipsen contacts****Investors**

**Craig Marks** +44 (0)7584 349 193  
**Nicolas Bogler** +33 6 52 19 98 92

**Media**

**Amy Wolf** +41 79 576 07 23  
**Ioana Piscociu** +33 6 69 09 12 96